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AbstrACt
Objective To investigate documentation of antimicrobial 
allergy and to determine prescribing adherence to local 
antibiotic guidelines for inpatients with and without 
reported penicillin allergy treated for infection in a National 
Health Service (NHS) context.
setting Data were collected at two English hospital NHS 
trusts over two time-periods: June 2016 and February 
2017.
Design Cohort study. Trust 1 data were sourced from 
prospective point prevalence surveys. Trust 2 data were 
extracted retrospectively from an electronic report.
Participants Inpatients treated for urinary tract 
infection (UTI), community-acquired pneumonia (CAP), 
hospital-acquired pneumonia (HAP) and skin and soft 
tissue infection (SSTI). Data on allergy were collected, 
and antibiotic selection assessed for adherence to trust 
guidelines with differences between groups presented as 
adjusted ORs.
results A total of 1497 patients were included, with 2645 
antibiotics orders. Patients were treated for CAP (n=495; 
33.1%), UTI (407; 27.2%), HAP (330; 22%) and SSTI (265; 
17.7%). There were 240 (16%) patients with penicillin 
allergy. Penicillin allergy was recorded as allergy (n=52; 
21.7%), side effect (27; 11.3%) and no documentation 
(161; 67.1%). Overall, 2184 (82.6%) antibiotic orders were 
guideline-adherent. Adherence was greatest for those 
labelled penicillin allergy (453 of 517; 87.6%) versus no 
allergy (1731 of 2128; 81.3%) (OR 0.52 (95% CI 0.37 to 
0.73) p<0.001). Guideline-adherence for CAP was higher if 
penicillin allergy (151 of 163; 92.6%) versus no allergy (582 
of 810; 71.9%) (OR 0.20 (95% CI 0.10 to 0.37) p<0.001). 
There was no difference in adherence between those with 
and without penicillin allergy for UTI, HAP or SSTI treatment.
Conclusions A relatively high proportion of patients had a 
penicillin allergy and two thirds of these had no description 
of their allergy, which has important implications for 
patient safety. Patients with penicillin allergy treated for 
CAP, received more guideline adherent antibiotics than 
those without allergy. Future studies investigating the 
clinical impact of penicillin allergy should include data on 
adherence to antibiotic guidelines.
IntrODuCtIOn 
Penicillin allergy can be a serious and life 
threatening reaction and reduces the choice 
of antibiotics available to treat infection with 
this first-line antibiotic.1 It is reported that 
10% of the UK population have a penicillin 
allergy with approximately one-fifth of these 
being a true allergy,2 3 and many deemed 
spurious.4 Penicillin allergy is frequently 
documented in hospitalised patients,5 6 yet 
few patients with a reported penicillin allergy 
ever get this diagnosis verified.7 The impor-
tance of clinicians elucidating a clear history 
(of specific agent, dose, duration, onset and 
resolution of symptoms) have been well 
stated.2 8 Unfortunately, there is inconsistency 
in the documentation of antimicrobial aller-
gies by practitioners and the details of allergy 
are frequently not recorded.9 
Studies have reported that patients with 
a reported penicillin allergy have extended 
strengths and limitations of this study
 ► This study contains multisite data providing adher-
ence rates to antibiotic guidelines for inpatients with 
penicillin allergy treated for active infection.
 ► This cohort study provides data on the extent of 
penicillin allergy documentation in a large National 
Health Service cohort which is meaningful as much 
of the data on this topic is from outside England.
 ► The infections captured in this study account for 
half of all indications requiring antibiotic treatment 
in hospital, which gives strength to generalisability 
to our findings.
 ► Confounding bias cannot be excluded as no infor-
mation was collected on comorbidities, presence of 
febrile illness or immune suppression which may 
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length of hospital stay, poorer clinical outcomes, 
increased risk of secondary infection or colonisation 
with multi-resistant organisms, and are more likely to 
be prescribed agents that are non-compliant with guide-
lines or are otherwise inappropriate compared with those 
with no penicillin allergy.10 11 It is unclear if these infe-
rior outcomes and increased use of antibiotics that are 
non-compliant to guidelines are the result of alternative 
agents being inherently less effective than penicillins 
at treating infection, or that clinicians are not selecting 
the most appropriate alternative agents for use in peni-
cillin allergy as determined by experts in institutional or 
national guidelines. Data from point-prevalence surveys 
shows antibiotic treatment for respiratory tract infections 
(28.9%), urinary tract infections (UTIs) (13.5%) and 
skin and soft tissue infections (SSTIs) (11%) account 
for half of all indications requiring antibiotic treatment 
in hospital.12 13 Trust guidelines recommend first-line 
antibiotics for these infections, usually penicillin or β-lac-
tams, while for patient with penicillin allergy, alternative 
agents structurally unrelated to penicillin or β-lactams 
antibiotics are recommended. We sought to investigate 
the impact of penicillin allergy status on the selection of 
antibiotics received by hospital inpatients with concur-
rent infection with the frequently occurring conditions 
of SSTI, community-acquired pneumonia (CAP), hospi-
tal-acquired pneumonia (HAP) and UTI. The extent of 
detail recorded for patients with penicillin allergy at these 
trusts is unknown as are guideline-adherence rates for 
prescribing in penicillin allergy. Our hypothesis was that 
the selection of antibiotics by clinicians for patients with 
penicillin allergy would be less guideline adherent than 
those without penicillin allergy, and that there would be 
a high proportion of patient with inadequate description 
of their reported allergy.
MethODs
study objectives
The objectives of this study were to (i) describe the docu-
mentation of allergy record in the electronic health 
record (EHR) and (ii) to determine to what extent clini-
cians treating patients with active infection in hospital are 
prescribing antibiotics adherent to local trust guidelines 
for those with (and without) penicillin allergy.
study design and dataset
This was a cohort study that sourced patient data from 
two large tertiary referral National Health Service (NHS) 
hospital trusts in England. Data were extracted over two 
time-periods of 6–17 June 2016 and 13–24 February 2017. 
We studied all inpatients ≥18 years with and without 
penicillin allergy with a current diagnosis of UTI, CAP, 
HAP and SSTI in the study period. Diagnoses were 
determined by treating clinicians. The indications were 
selected as these infections occur frequently and both 
trusts have clear guidance on alternate antibiotic for use 
in penicillin allergy for these indications. Both trusts had 
EHRs in operation prior to and for the duration of the 
study period. Clinician access to guidelines was via trust 
intranet. Trust 1 data were sourced from point prevalence 
surveys where data were collected prospectively from ward 
visits Monday to Friday as previously described.14 Trust 2 
data were captured retrospectively from an EHR report 
covering the full duration of each study period.
Coding of allergy
Documentation of allergy/adverse drug reaction (ADR) 
status was coded as ‘allergy’, ‘side-effect’, or ‘no docu-
mentation’, determined from information recorded in 
the allergy/ADR field and any corroborative information 
in the EHR.
Assessment of antibiotics for adherence to trust guidelines
While both trusts are NHS institutions, each had its own 
antibiotic guideline for treatment of infection. There 
were similarities in the antibiotic agents stated in both 
guidelines for the included indications of CAP, HAP, SSTI 
and UTI. However, some notable differences in recom-
mended antibiotics between the two guidelines were 
present when treating, severe CAP in penicillin allergy; 
severe HAP when no allergy; complicated cellulitis in 
both penicillin allergy and no allergy; and for uncompli-
cated UTI (online supplementary material).
Medication orders were assessed for adherence of 
antibiotic agents to respective trust guidelines for those 
patients with reported penicillin allergy or for those 
without penicillin allergy, whichever applied by allergy 
status. If the antibiotic order was for the stated antibi-
otic in the respective trust’s guideline, for the indication 
in question, it was assessed as adherent. Conversely, if a 
patient had not received the guideline recommended 
antibiotic, the antibiotic order was assessed as non-ad-
herent. Adherence was assessed by experienced clinical 
pharmacists, who work closely with medical microbiolo-
gists and infectious diseases physicians in their clinical 
roles. Ambiguous cases were adjudicated by a second 
investigator.
Patient and public involvement
Patients and the public were not directly involved in this 
study; however, patient data resource and access were 
approved by the respective research governance offices 
of each institution.
statistical analysis
Differences between groups in the frequency of patient 
characteristics were compared using a two-sample test 
of proportions. Differences between groups in age and 
other continuous variables were compared using an 
independent t-test. Adherence of antibiotics to trust 
guidelines was described using frequency counts and 
percentages. Differences in adherence between patients 
with and without penicillin allergy was assessed using 
univariate and multivariate (age and sex adjusted) binary 
logistic regression with results expressed as ORs with 
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for the clustering of prescriptions for a patient. Specialty 
of treating team was not available for all antibiotic order 
data, as such we were not able to include that variable 
in multivariate regression. A p value<0.05 was used to 
define statistical significance. All statistical analyses were 
performed using STATA V.15.0 (StataCorp, Texas, USA).
results
Patient characteristics
There were 2645 antibiotic medication orders from a 
population of 1497 adult patients over the study duration. 
Study flow diagram is presented in figure 1. Thirty-five 
paediatric patients were excluded. Overall, patients had a 
median age of 73 (IQR 56–82) years, 50.2% were female 
and 1131 (75.5%) treated by medical teams. There were 
some differences observed for those with reported peni-
cillin allergy; more female sex 60% versus 48% p=0.001, 
and notably more allergies to other antibiotics 34.6% 
versus 6.5% p≤0.001. Patients were treated for the indi-
cations of CAP (495; 33.1%), UTI (407; 27.2%), HAP 
(330; 22%) and SSTI (265; 17.7%). Patient characteristics 
overall and for those with and without reported penicillin 
allergy are presented in table 1.
Allergy
There were 341 (22.7%) patients with a reported antimi-
crobial allergy. In the 240 (16%) patients where penicillin 
allergy was reported in the EHR, the specific agent was 
recorded in 70 (29.2%). The median age of patients with 
penicillin allergy was 73 years (58–85) and 60% female. 
Overall there were 175 non-penicillin antimicrobial 
allergies documented, with more allergies observed in 
those with reported penicillin; macrolides (8.8% vs 1.4% 
p≤0.001); trimethoprim (6.3% vs 1% p≤0.001) and quino-
lones (5.4% vs 1% p≤0.001) accounting for half (52%) 
of these allergies (table 1). Labelling of penicillin aller-
gies was identified as allergy (52; 21.7%), side effect (27; 
11.3%) and no documentation (161; 67.1%) (table 2). 
Frequency and per cent of reported ADR/allergy label for 
other antibiotics is presented for those with and without 
reported penicillin allergy (table 3).
Assessment of antibiotics for adherence to trust guidelines
Overall, 2184 of 2645 (82.6%) of medication orders 
were adherent to trust antibiotic guidelines. Adherence 
of medication orders to trust antibiotic guidelines for 
all and by penicillin allergy status is shown in figure 2. 
Overall adherence was greatest where penicillin allergy 
was recorded (453 of 517; 87.6%) versus no penicillin 
allergy (1731 of 2128; 81.3%) (adjusted OR 0.52 (95% CI 
0.37 to 0.73) p<0.001). Adherence to guidelines for anti-
biotics prescribed for CAP was greater for those with 
penicillin allergy (151 of 163; 92.6%) versus no penicillin 
allergy (582 of 810; 71.9%) (adjusted OR 0.21 (95% CI 
0.11 to 0.37) p<0.001). Medication orders for UTI were 
more adherent to guidelines if patients had no penicillin 
allergy (486 of 539; 90.2%) versus penicillin allergy (95 of 
116; 81.9%) (unadjusted OR 2.03 (95% CI 1.11 to 3.60) 
p=0.011), however, the there was no difference in the 
adjusted OR (OR 1.52 (0.65–3.51) p=0.332). For the indi-
cations of HAP and SSTI there was no differences between 
those with and without penicillin allergy (table 4).
DIsCussIOn
In our study, almost one-quarter (23%) of patients had an 
antimicrobial allergy label in the EHR and a staggering 
16% had a penicillin allergy label. Our prevalence of 
penicillin allergy is considerable higher than the 10% 
figure often stated in the literature,15 yet very similar to a 
number of other hospital-based studies where penicillin 
allergy was found in 14%–16% of patients.16 17 Further-
more, this incidence of penicillin allergy may reflect the 
relatively high median age of our population, as others 
have found increasing age to be associated with peni-
cillin allergy.18 Penicillin allergy was overwhelmingly the 
most commonly reported antimicrobial allergy found, 
which is consistent with that reported by others.19 We 
were concerned to find that two-thirds of patients with a 
reported penicillin allergy had an absence of any descrip-
tion in the EHR regarding their allergy. Such a high 
proportion of patients with no further information on 
their allergy is alarming. Interestingly, others have also 
reported lack of allergy description regarding penicillin 
allergy in up to 80% of patients in hospital,20 and 77% of 
those in community care.9 While a record of penicillin 
allergy status may have been entered into the health 
record at a prior episode of care, and possibly a long 
time ago,21 22 it is incumbent on clinicians providing care 
Figure 1 Study flow diagram. CAP, community acquired 
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do more to enquire, contact the provider facility where 
the event was first recorded, and detail the nature of the 
penicillin reaction. At a very minimum, clinicians should 
describe what steps were taken to clarify the record, and 
if the patient is suitable for referral to allergy or immu-
nology to confirm or de-label their reported penicillin 
allergy.16 This approach has increasingly been advocated 
as an antimicrobial stewardship strategy,23 and has been 
successfully adopted by others.24
In this study, we found that patients with penicillin 
allergy overall received antibiotics that were significantly 
more adherent to guidelines (88%) when compared with 
those without penicillin allergy. This finding was higher 
than that reported in a small hospital study (n=94), 
investigating clinical implications of β-lactam allergy, 
which found adherence to antibiotic guidelines was 81%, 
however, patients without penicillin allergy were not 
included in that study.25
We hypothesised that patients with penicillin allergy 
would be prescribed antibiotics that were overall less 
guideline adherent than those with no penicillin allergy. 
Our hypothesis was based on a recent large study 
(n=21 031) that found patients with documented anti-
microbial allergy had less guideline compliant agents 
prescribed compared with those without allergy (78.7% vs 
79.2%, p=0.001).10 Our hypothesis was initially observed 
for patients with UTI, where penicillin allergy was asso-
ciated with receiving less guideline adherent antibiotics, 
however, when we performed multivariate analysis, the 
adjusted ORs did not show any effect.
Table 1 Patient characteristics, allergy status and indication for therapy






Age, years median (IQR) 73 (56–82)  73 (55–84) 73 (55–84) 0.745
Sex, female 752 (50.2) 144 (60) 602 (48) 0.001
Specialty
  Medicine 683 (45.6) 109 (45.4) 574 (45.6) 0.944
  Acute medicine 295 (19.7) 49 (20.4) 246 (19.5) 0.763
  Elderly medicine 153 (10.2) 23 (9.6) 130 (10.3) 0.029
  Specialist surgical 265 (17.7) 42 (17.5) 223 (17.7) <0.001
  General surgical 94 (6.3) 16 (6.7) 78 (6.2) 0.787
  Private 7 (0.5) 1 (0.4) 6 (0.5) 1.000
Antibiotic allergies/adverse drug 
reaction 
165 (11) 83 (34.6) 82 (6.5) <0.001
  Macrolides 39 (2.6) 21 (8.8) 18 (1.4) <0.001
  Trimethoprim 27 (1.8) 15 (6.3) 12 (1) <0.001
  Quinolones 25 (1.7) 13 (5.4) 12 (1) <0.001
  Nitrofurantoin 18 (1.2) 9 (3.8) 9 (0.7) <0.001
  Sulfonamides 17 (1.1) 6 (2.5) 11 (0.9) 0.029
  Tetracyclines 7 (0.5) 4 (1.7) 3 (0.2) 0.015
  Glycopeptide 7 (0.5) 1 (0.4) 6 (0.5) 0.688
  Cephalosporins 7 (0.5) 5 (2.1) 2 (0.2) 0.002
  Metronidazole 6 (0.4) 3 (1.3) 3 (0.2) 0.056
  Meropenem 5 (0.3) 4 (1.7) 1 (0.1 0.003
  Clindamycin 4 (0.3) 1 (0.4) 3 (0.2) 0.503
  Aminoglycoside 3 (0.2) 1 (0.4) 2 (0.2) 0.408
Indications for antibiotic treatment
  Community-acquired pneumonia 495 (33.1) 73 (30.4) 422 (33.6) 0.341
  Urinary tract infection 407 (27.2) 64 (26.7) 343 (27.3) 0.843
  Hospital-acquired pneumonia 330 (22) 55 (22.9) 275 (21.9) 0.143
  Bacterial skin and soft tissue 
infection
265 (17.7) 50 (20.8) 215 (17.1) 0.165
*Data reported as n (%) unless otherwise stated.
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Our finding that patients with penicillin allergy overall 
received antibiotics that were more guideline-adherent 
was driven by patients being treated for CAP. While 
patients with reported penicillin allergy received antibi-
otics that were more guideline adherent for CAP, those 
patients were receiving macrolides, tetracyclines and 
or quinolones over first-line amoxicillin-based therapy. 
Additionally, patients with penicillin allergy received 
clindamycin or a macrolide rather than first-line fluclox-
acillin in cellulitis, and nitrofurantoin or quinolones for 
UTI rather than penicillin-based agent. The high level of 
prescribing adherence to treatment guidelines in CAP 
for those with penicillin allergy, may have been due to 
trust guidelines typically recommending a single antibi-
otic, except for those with the most severe presentations 
of CAP. This is in contrast to guideline recommenda-
tions for those without allergy, where guidelines suggest 
two antibiotics for treatment of CAP for all but the least 
severe presentations. Thus, it may have been easier for 
clinicians to prescribe one antibiotic in penicillin allergy, 
rather than two for those without allergy. Furthermore, it 
is also possible that clinicians were less certain of which 
antibiotic to prescribe in penicillin allergy and therefore 
consulted trust guidelines more readily than they did for 
those without allergy.
When interpreting our findings, both participating 
trusts had locally endorsed guidelines, which were readily 
accessible, containing clear advice on alternative agents 
to use for patients with penicillin allergy for all the indi-
cations included in this study. Studies describing poor 
outcomes and greater use of non-compliant antibiotics 
in hospitalised, in often complex, immunocompromised 
patients frequently provide little or no detail about the 
presence or access to endorsed guidelines, or guideline 
adherence in those respective institutions, or if such 
guidelines provide advice on penicillin allergy for the 
specific indications in question.10 16 26–28
While our study was conducted in tertiary institutions, 
we deliberately selected frequently occurring indica-
tions that are managed in large and small facilities across 
the county. We propose freely accessible, updated and 
endorsed antibiotic guidelines with clear alternative 
recommendations in penicillin allergy for most indica-
tions, would be a valuable recommendation for hospitals 
that do not currently have these available. Furthermore, 
we recommend better allergy documentation, and testing. 
Providing ready-access to other contemporaneous guide-
lines may go some way to limiting the inferior outcomes 
observed for those with penicillin allergy. Vancomycin has 
been reported as the most frequently used non β-lactam 
Table 2 Reported reaction to penicillin and identified 
agents
Reported reaction to penicillin n=240
Allergy 52 (21.7)
Side effect 27 (11.3)
No documentation 161 (67.1)
Penicillin agent reported as allergic
  Penicillin (unspecified) 170 (70.8)
  Co-amoxiclav 20 (8.3)
  Piperacillin-tazobactam 18 (7.5)
  Amoxicillin/ampicillin 17 (7.1)
  Flucloxacillin 14 (5.8)
  Phenoxymethylpenicillin 1 (0.4)






Non-penicillin antibiotic allergy† 175 83 92
  Allergy 22 (12.6) 12 (14.5) 10 (10.9) 0.475
  Side effect 28 (16) 9 (10.8) 19 (20.7) 0.077
  No documentation 125 (71.4) 62 (74.7) 63 (68.5) 0.363
Data reported as n (%).
*Two-sample test of proportions.
†Ten patients have both allergy and side effect reported.
Figure 2 Adherence of medication orders to trust antibiotic 
guidelines by penicillin allergy status. CAP, community 
acquired pneumonia; HAP, hospital acquired pneumonia; 
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agent in hospitalised patients with penicillin allergy 
treated for infection,6 27 with rates of usage in those with 
penicillin allergy ranging from 39%– to 66%.17 26 Vanco-
mycin is known to be an inferior agent in the prevention 
of surgical site infections by meticillin-sensitive Staphylo-
coccus aureus compared with penicillins and β-lactams.29 
Additionally, a recent study found patients with reported 
penicillin allergy undergoing surgery had an increased 
risk of surgical site infection compared with those with no 
allergy when prescribed antibiotic prophylaxis with alter-
nate agents such vancomycin.30
The current study has a number of strengths. Data 
were collected from patients treated at multiple sites, in 
different organisations from in two geographical regions 
of England. Furthermore, this is meaningful as most of 
the data on this topic is from outside England. While the 
study was conducted in tertiary referral centres, the infec-
tions treated are common and likely to be treated in all 
hospitals regardless of size, which gives strength to the 
generalisability of the results.
limitations
This work is not without limitations. The study included 
retrospective data and was a cohort study, which cannot 
exclude confounding bias. No information on comorbid-
ities, presence of febrile illness, immune suppression, or 
microbiology was collected which may have influenced 
the selection of antibiotics and ultimately guideline 
adherence rates. During multivariate regression model, 
we were unable to include the specialty of treating teams 
in the model as this data variable was not available for all 
antibiotic orders. Following-up clinical data and patient 
outcomes were not assessed in this study; further studies 
in this field should consider including outcomes such as 
length of stay, readmission rates, treatment failures and 
ADRs.
COnClusIOn
In this study, we found a high proportion of hospital 
inpatients had reported penicillin compared with the 
known prevalence of penicillin allergy in the community. 
Importantly two-thirds of these penicillin allergies had 
no further details whatsoever of the nature of the allergy 
in the patients’ EHR. This lack of information leads to 
uncertainty in making clinical decisions and may have 
important implications for patient safety. In contrast 
to previous studies, in the current study we found that 
patients with a reported penicillin allergy were more 
likely to be prescribed antibiotics that were adherent to 
local guidelines, which may reflect the existence of unam-
biguous detailed guidance for antibiotic selection in peni-
cillin allergy in the study institutions. Future studies on 
prescribing in penicillin allergy should include data on 
adherence to guidelines and seek to further understand 
the implications of this effect.
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OR (95% CI)* P value*
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